All In Biotech

Drug Trial Radar · NCT06661733

A Study to Investigate the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment

A Phase I Single Dose, Non-Randomised, Open-Label, Parallel Group Study to Assess the Pharmacokinetics, Safety and Tolerability of AZD5462 in Participants With Renal Impairment

Last checked: Nov 19, 2026Latest source record: Dec 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Nov 18, 2024

Primary completion

Dec 23, 2024

Study completion Dec 23, 2024

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 28, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of AZD5462 in participants with impaired renal function.

Conditions

  • Renal Impairment

Interventions

  • AZD5462Drug

    Participants will receive AZD5462 orally.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under plasma concentration-time curve from time 0 to infinity (AUCinf)Time frame: Day 1 to Day 4
  2. Area under the plasma concentration-time curve from time 0 to the last quantifiable concentration (AUClast)Time frame: Day 1 to Day 4
  3. Time to reach maximum observed plasma concentration (tmax)Time frame: Day 1 to Day 4
  4. Maximum observed plasma concentration (Cmax)Time frame: Day 1 to Day 4
  5. Terminal elimination rate constant (λz)Time frame: Day 1 to Day 4
  6. Terminal elimination half-life (t½λz)Time frame: Day 1 to Day 4
  7. Apparent total body clearance (CL/F)Time frame: Day 1 to Day 4
  8. Non-renal clearance of drug from plasma (CLNR/F)Time frame: Day 1 to Day 4
  9. Apparent volume of distribution based on the terminal phase (Vz/F)Time frame: Day 1 to Day 4
  10. Renal clearance of drug (CLR)Time frame: Day 1 to Day 2

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Sofia, Bulgaria

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.